SLS logo

SELLAS Life Sciences (SLS) Company Overview

Profile

Full Name:

SELLAS Life Sciences Group, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

March 12, 2008

Indexes:

Not included

Description:

SELLAS Life Sciences is a biopharmaceutical company focused on developing innovative cancer treatments. They work on immunotherapies and personalized medicine to improve patient outcomes. Their goal is to advance therapies that can effectively target and fight various types of cancer.

Events Calendar

Earnings

Next earnings date:

May 14, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 23, 2021
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 8, 2019

Analyst ratings

Recent major analysts updates

Nov 22, 23 Cantor Fitzgerald
Overweight
Sep 7, 23 Cantor Fitzgerald
Overweight
Nov 15, 22 Alliance Global Partners
Buy
Jun 28, 22 Cantor Fitzgerald
Overweight
Jul 21, 21 Cantor Fitzgerald
Overweight
Nov 18, 19 Oppenheimer
Outperform
Nov 18, 19 Maxim Group
Buy
Nov 18, 19 H.C. Wainwright
Buy
Nov 18, 19 Alliance Global Partners
Buy
Nov 15, 19 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

SELLAS Announces Key Business Objectives for 2025
SELLAS Announces Key Business Objectives for 2025
SELLAS Announces Key Business Objectives for 2025
SLS
globenewswire.comJanuary 8, 2025

- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 - - Approval of “tambiciclib” as Recommended International Nonproprietary Name for SLS009 - - Applied for Non-Dilutive Grant Funding to Expand SLS009 Development Into Frontline Setting in AML - - Developing SLS009 Pediatric Programs in Hematological and Potentially Other Malignancies - - Company to Host Corporate Update Webinar Today, January 8, 2025, at 9:00 am ET - NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and will host a webinar at 9:00 am ET. “We believe that 2025 will be a pivotal year for SELLAS as we continue to advance our clinical stage portfolio of novel therapeutics for hematologic malignancies,” said Angelos Stergiou, MD, ScD h.c.

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
SLS
globenewswire.comDecember 9, 2024

- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
SLS
globenewswire.comNovember 27, 2024

- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers –

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SLS
globenewswire.comNovember 13, 2024

– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 –

Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
SLS
prnewswire.comSeptember 24, 2024

-Dosing of the SLS-002 cohort is expected to commence in 4Q2024 NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the signing of a Material Transfer Agreement (MTA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) to supply SLS-002 (intranasal racemic ketamine) for the U.S. Department of Defense's (DOD) Military and Veterans Adaptive Platform Clinical Trial ("M-PACT") to evaluate its potential for treatment of post-traumatic stress disorder (PTSD).

Galena Biopharma (SLS) Upgraded to Buy: Here's Why
Galena Biopharma (SLS) Upgraded to Buy: Here's Why
Galena Biopharma (SLS) Upgraded to Buy: Here's Why
SLS
zacks.comAugust 20, 2024

Galena Biopharma (SLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
SLS
globenewswire.comAugust 13, 2024

- Announced Independent Data Monitoring Committee's (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis Anticipated by Q4 2024 -

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
SLS
globenewswire.comAugust 6, 2024

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) for SLS009, a novel, and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL).

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
SLS
globenewswire.comJuly 16, 2024

- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers –

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
SLS
globenewswire.comJuly 8, 2024

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the European Commission, based on a positive opinion issued by the European Medicines Agency (EMA), has granted Orphan Drug Designation (ODD) for SLS009, a novel, and highly selective CDK9 inhibitor, for the treatment of acute myeloid leukemia (AML).

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for SELLAS Life Sciences?
  • Does SELLAS Life Sciences pay dividends?
  • What sector is SELLAS Life Sciences in?
  • What industry is SELLAS Life Sciences in?
  • What country is SELLAS Life Sciences based in?
  • When did SELLAS Life Sciences go public?
  • Is SELLAS Life Sciences in the S&P 500?
  • Is SELLAS Life Sciences in the NASDAQ 100?
  • Is SELLAS Life Sciences in the Dow Jones?
  • When was SELLAS Life Sciences's last earnings report?
  • When does SELLAS Life Sciences report earnings?
  • Should I buy SELLAS Life Sciences stock now?

What is the ticker symbol for SELLAS Life Sciences?

The ticker symbol for SELLAS Life Sciences is NASDAQ:SLS

Does SELLAS Life Sciences pay dividends?

No, SELLAS Life Sciences does not pay dividends

What sector is SELLAS Life Sciences in?

SELLAS Life Sciences is in the Healthcare sector

What industry is SELLAS Life Sciences in?

SELLAS Life Sciences is in the Biotechnology industry

What country is SELLAS Life Sciences based in?

SELLAS Life Sciences is headquartered in United States

When did SELLAS Life Sciences go public?

SELLAS Life Sciences's initial public offering (IPO) was on March 12, 2008

Is SELLAS Life Sciences in the S&P 500?

No, SELLAS Life Sciences is not included in the S&P 500 index

Is SELLAS Life Sciences in the NASDAQ 100?

No, SELLAS Life Sciences is not included in the NASDAQ 100 index

Is SELLAS Life Sciences in the Dow Jones?

No, SELLAS Life Sciences is not included in the Dow Jones index

When was SELLAS Life Sciences's last earnings report?

SELLAS Life Sciences's most recent earnings report was on Nov 13, 2024

When does SELLAS Life Sciences report earnings?

The next expected earnings date for SELLAS Life Sciences is May 14, 2025

Should I buy SELLAS Life Sciences stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions